These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 19223541)
1. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Sen B; Saigal B; Parikh N; Gallick G; Johnson FM Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541 [TBL] [Abstract][Full Text] [Related]
2. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Johnson FM; Saigal B; Tran H; Donato NJ Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553 [TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Nam S; Wen W; Schroeder A; Herrmann A; Yu H; Cheng X; Merz KH; Eisenbrand G; Li H; Yuan YC; Jove R Mol Oncol; 2013 Jun; 7(3):369-78. PubMed ID: 23206899 [TBL] [Abstract][Full Text] [Related]
4. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Sen B; Peng S; Woods DM; Wistuba I; Bell D; El-Naggar AK; Lai SY; Johnson FM Clin Cancer Res; 2012 Jan; 18(1):127-39. PubMed ID: 22090359 [TBL] [Abstract][Full Text] [Related]
5. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010 [TBL] [Abstract][Full Text] [Related]
6. Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: Role in apoptosis induction and radiosensitization in head and neck tumor cells. Baek SH; Ko JH; Lee H; Jung J; Kong M; Lee JW; Lee J; Chinnathambi A; Zayed ME; Alharbi SA; Lee SG; Shim BS; Sethi G; Kim SH; Yang WM; Um JY; Ahn KS Phytomedicine; 2016 May; 23(5):566-77. PubMed ID: 27064016 [TBL] [Abstract][Full Text] [Related]
7. MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells. Liu L; Gaboriaud N; Vougogianopoulou K; Tian Y; Wu J; Wen W; Skaltsounis L; Jove R Cancer Biol Ther; 2014 Feb; 15(2):178-84. PubMed ID: 24100507 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Lee TL; Yeh J; Van Waes C; Chen Z Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158 [TBL] [Abstract][Full Text] [Related]
9. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227 [TBL] [Abstract][Full Text] [Related]
10. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Byers LA; Sen B; Saigal B; Diao L; Wang J; Nanjundan M; Cascone T; Mills GB; Heymach JV; Johnson FM Clin Cancer Res; 2009 Nov; 15(22):6852-61. PubMed ID: 19861436 [TBL] [Abstract][Full Text] [Related]
11. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308 [TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660 [TBL] [Abstract][Full Text] [Related]
13. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells. Wei J; Ma L; Li C; Pierson CR; Finlay JL; Lin J Curr Cancer Drug Targets; 2019; 19(7):571-582. PubMed ID: 30332965 [TBL] [Abstract][Full Text] [Related]
14. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma. Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539 [TBL] [Abstract][Full Text] [Related]
15. Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling. Jia L; Song Q; Zhou C; Li X; Pi L; Ma X; Li H; Lu X; Shen Y PLoS One; 2016; 11(1):e0147157. PubMed ID: 26784960 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib. Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967 [TBL] [Abstract][Full Text] [Related]
17. MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma. Peng HY; Cheng YC; Hsu YM; Wu GH; Kuo CC; Liou JP; Chang JY; Jin SL; Shiah SG PLoS One; 2016; 11(7):e0158440. PubMed ID: 27367272 [TBL] [Abstract][Full Text] [Related]
18. JAK2 regulation by licochalcone H inhibits the cell growth and induces apoptosis in oral squamous cell carcinoma. Oh HN; Oh KB; Lee MH; Seo JH; Kim E; Yoon G; Cho SS; Cho YS; Choi HW; Chae JI; Shim JH Phytomedicine; 2019 Jan; 52():60-69. PubMed ID: 30599913 [TBL] [Abstract][Full Text] [Related]
19. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076 [TBL] [Abstract][Full Text] [Related]
20. JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway. Fang J; Chu L; Li C; Chen Y; Hu F; Zhang X; Zhao H; Liu Z; Xu Q Oncol Rep; 2015 Jan; 33(1):494-502. PubMed ID: 25405520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]